Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03141112
Other study ID # ECRRT 51/16
Secondary ID
Status Enrolling by invitation
Phase N/A
First received May 2, 2017
Last updated May 3, 2017
Start date August 2016
Est. completion date December 2020

Study information

Verified date May 2017
Source University Hospital Olomouc
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study will evaluate the benefit of early initiation of CRRT in the initial phase of severe sepsis in patients admitted to the ICU. Primary evaluated end-point is 28-day mortality. Secondarily evaluated end-point is length of ICU-stay, length of stay in hospital, duration of mechanical ventilation. There are two groups. One group of participants with early CRRT initiation and another group with late CRRT initiation. Reference group no CRRT.


Description:

The aim is to determine the optimal timing of initiation of CRRT with respect to the degree and duration of acute kidney injury (AKI) in ICU patients. The CRRT parameters and the duration of therapy will be monitored, depending on initial biochemical and clinical values of the patient. Part of the study is the follow-up of patients with a 3-month delay.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 200
Est. completion date December 2020
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- reaching criteria of severe sepsis, ICU admission

Exclusion Criteria:

- pregnant women, younger than 18 years, reaching contraindications for initiation of renal replacement therapy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
renal replacement therapy


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Radovan Uvizl

Outcome

Type Measure Description Time frame Safety issue
Other length of stay length of stay in hospital 3 months
Primary mortality yes/no 28 days
Secondary duration of mechanical ventilation days of mechanical ventilation including weening 28 days
See also
  Status Clinical Trial Phase
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Completed NCT02539147 - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis N/A
Completed NCT01929772 - German Lactat Clearance in Severe Sepsis N/A
Completed NCT01932814 - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful? N/A
Completed NCT01449721 - Preemptive Resuscitation for Eradication of Septic Shock N/A
Active, not recruiting NCT01162109 - Zinc Therapy in Critical Illness Phase 1
Not yet recruiting NCT01211899 - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock N/A
Completed NCT00934011 - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections N/A
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00463645 - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients N/A
Completed NCT02361528 - GM-CSF to Decrease ICU Acquired Infections Phase 3
Completed NCT02734550 - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis N/A
Completed NCT02973243 - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Completed NCT01945983 - Early Use of Norepinephrine in Septic Shock Resuscitation N/A
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A